These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 24286577)

  • 1. The sympathetic nervous system and heart failure.
    Zhang DY; Anderson AS
    Cardiol Clin; 2014 Feb; 32(1):33-45, vii. PubMed ID: 24286577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
    Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
    J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic heart failure: a disease of the brain.
    Singh RB; Hristova K; Fedacko J; El-Kilany G; Cornelissen G
    Heart Fail Rev; 2019 Mar; 24(2):301-307. PubMed ID: 30341700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human sympathetic nervous system: its relevance in hypertension and heart failure.
    Parati G; Esler M
    Eur Heart J; 2012 May; 33(9):1058-66. PubMed ID: 22507981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure.
    Francis GS
    Am Heart J; 1989 Sep; 118(3):642-8. PubMed ID: 2570521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic therapy of chronic heart failure.
    Hamad E; Mather PJ; Srinivasan S; Rubin S; Whellan DJ; Feldman AM
    Am J Cardiovasc Drugs; 2007; 7(4):235-48. PubMed ID: 17696565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating patients with severe heart failure.
    Eichhorn EJ
    Postgrad Med; 2002 Nov; 112(5 Suppl Unanswered):24-31. PubMed ID: 19667605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary medical management of systolic heart failure.
    Nair AP; Timoh T; Fuster V
    Circ J; 2012; 76(2):268-77. PubMed ID: 22240600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of heart failure: the role of neurohumoral activation.
    Middlekauff HR; Mark AL
    Intern Med; 1998 Feb; 37(2):112-22. PubMed ID: 9550589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R; McMurray JJ
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The control of adrenergic function in heart failure: therapeutic intervention.
    Clark AL; Cleland JG
    Heart Fail Rev; 2000 Mar; 5(1):101-14. PubMed ID: 16228919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Programs for continuing medical education: B session; 1. The pathophysiology of heart failure--is it the disease of the heart?].
    Kitakaze M
    Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):681-6. PubMed ID: 24796136
    [No Abstract]   [Full Text] [Related]  

  • 14. The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction.
    Floras JS; Ponikowski P
    Eur Heart J; 2015 Aug; 36(30):1974-82b. PubMed ID: 25975657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between the sympathetic nervous system and the RAAS in heart failure.
    Goldsmith SR
    Curr Heart Fail Rep; 2004 Jul; 1(2):45-50. PubMed ID: 16036024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased central nervous system monoamine neurotransmitter turnover and its association with sympathetic nervous activity in treated heart failure patients.
    Lambert GW; Kaye DM; Lefkovits J; Jennings GL; Turner AG; Cox HS; Esler MD
    Circulation; 1995 Oct; 92(7):1813-8. PubMed ID: 7545554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
    van Diepen S; Reynolds HR; Stebbins A; Lopes RD; Džavík V; Ruzyllo W; Geppert A; Widimsky P; Ohman EM; Parrillo JE; Dauerman HL; Baran DA; Hochman JS; Alexander JH
    Crit Care Med; 2014 Feb; 42(2):281-8. PubMed ID: 23982033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.
    Dhaliwal AS; Bredikis A; Habib G; Carabello BA; Ramasubbu K; Bozkurt B
    Am J Cardiol; 2008 Nov; 102(10):1356-60. PubMed ID: 18993155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sympathetic nervous system in heart failure.
    Cohn JN
    Circulation; 2002 Nov; 106(19):2417-8. PubMed ID: 12417535
    [No Abstract]   [Full Text] [Related]  

  • 20. Innovations in the pharmacologic management of heart failure.
    Michael KA; Parnell KJ
    AACN Clin Issues; 1998 May; 9(2):172-91; quiz 327-8. PubMed ID: 9633271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.